Opthea Ltd

Opthea Ltd (OPT) priced its initial public offering on Oct 19, 2020 at $13.50 per ADS, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $569.8M. Citigroup was lead-left underwriter, joined by Leerink Partners, Oppenheimer and Truist. Cooley advised the company and Goodwin Procter and Herbert Smith Freehills advised the underwriters.

Opthea Ltd is a clinical-stage biopharmaceutical company developing OPT-302, a biologic that inhibits VEGF-C and VEGF-D, for retinal diseases such as wet age-related macular degeneration. It is designed to be used with VEGF-A inhibitors to broaden inhibition and help patients who respond poorly to current treatments.

Status

IPO

Ticker

OPT

Exchange

Nasdaq Global Select

Priced

Oct 19, 2020

IPO price

$13.50 per ADS

Market cap at IPO price

$569.8M

First filed

Sep 24, 2020

Underwriters

Citigroup, Leerink Partners, Oppenheimer and Truist

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter and Herbert Smith Freehills

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.